David Sommerhalder

1 month ago | nature.com | Yuxiang Ma |Yun Fan |Siqing Fu |Lin Wu |David Sommerhalder |Wei Lian | +2 more

AbstractAntibody–drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker.

Jun 24, 2024 | nature.com | Yeon Hee Park |David Sommerhalder |Kan Yonemori |Erika Hamilton |Toshinari Yamashita |Rachel M. Layman | +3 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03060-0, published online 1 June 2024In the version of the article initially published, in Extended Data Fig. 1, under “Part 1B”, “5 mg QD” originally read “3 dose levels” and “n=9” was missing from that box. There was originally an additional “Cohort 1 (5 mg QD, n=9)” box that has now been removed. Under “Part “2A”, the text “fulvestrant 500 mg” originally preceded “(n=35)”. In Extended Data Fig.

Jun 1, 2024 | nature.com | Yeon Hee Park |David Sommerhalder |Kan Yonemori |Erika Hamilton |Toshinari Yamashita |Rachel M. Layman | +3 more

AbstractInhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown antitumor activity in estrogen receptor-positive (ER+) breast cancer preclinical models. PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B.

Oct 18, 2023 | onclive.com | David Sommerhalder

October 18, 2023David Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer. David Sommerhalder, MD, medical oncologist, hematologist, Texas Oncology, director, Clinical Research, NEXT Oncology, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer (CRC).